ResMed Inc. (RMD) Income Statement Analysis

See more : Oxus Acquisition Corp. (OXUSW) Income Statement Analysis – Financial Results

Complete financial analysis of ResMed Inc. (RMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ResMed Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

ResMed Inc. (RMD)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.resmed.com

About ResMed Inc.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993
Revenue	4.69B	4.22B	3.58B	3.20B	2.96B	2.61B	2.34B	2.07B	1.84B	1.68B	1.55B	1.51B	1.37B	1.24B	1.09B	920.74M	835.40M	716.33M	607.00M	425.51M	339.34M	273.57M	204.08M	155.16M	115.62M	88.60M	66.50M	49.20M	34.60M	23.50M	13.90M	7.70M
Cost of Revenue	2.03B	1.87B	1.55B	1.36B	1.24B	1.07B	978.03M	864.99M	772.22M	667.52M	565.19M	573.80M	547.78M	501.82M	436.87M	366.93M	341.65M	331.84M	230.10M	150.65M	122.60M	100.48M	70.83M	50.38M	30.74M	24.80M	19.40M	17.70M	15.70M	10.70M	5.90M	2.90M
Gross Profit	2.66B	2.36B	2.02B	1.84B	1.72B	1.54B	1.36B	1.20B	1.07B	1.01B	989.79M	940.66M	820.74M	741.33M	655.48M	553.80M	493.75M	384.49M	376.90M	274.86M	216.74M	173.09M	133.25M	104.78M	84.87M	63.80M	47.10M	31.50M	18.90M	12.80M	8.00M	4.80M
Gross Profit Ratio	56.67%	55.78%	56.57%	57.53%	58.09%	58.95%	58.21%	58.15%	58.00%	60.24%	63.65%	62.11%	59.97%	59.63%	60.01%	60.15%	59.10%	53.68%	62.09%	64.60%	63.87%	63.27%	65.29%	67.53%	73.41%	72.01%	70.83%	64.02%	54.62%	54.47%	57.55%	62.34%
Research & Development	307.53M	287.64M	253.58M	225.28M	201.95M	180.65M	155.15M	144.47M	118.65M	114.87M	118.23M	120.12M	109.73M	92.01M	75.20M	63.06M	60.52M	50.11M	37.22M	30.01M	26.17M	20.53M	14.91M	11.15M	8.50M	6.50M	5.00M	3.80M	2.80M	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	600.37M	553.97M	488.06M	478.63M	450.41M	430.80M	401.62M	372.25M	331.86M	289.88M	278.09M	237.33M	200.17M	135.70M	104.71M	85.31M	64.48M	49.91M	36.99M	27.40M	21.10M	16.80M	11.10M	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-5.46M	-6.00M	0.00	0.00	0.00	-1.00M	-3.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	917.14M	874.00M	739.37M	670.39M	676.69M	645.01M	600.37M	553.97M	482.59M	472.63M	450.41M	430.80M	401.62M	371.25M	328.86M	289.88M	278.09M	237.33M	200.17M	135.70M	104.71M	85.31M	64.48M	49.91M	36.99M	27.40M	21.10M	16.80M	11.10M	9.40M	6.40M	3.90M
Other Expenses	110.75M	-5.71M	31.08M	31.08M	30.09M	74.94M	-8.54M	4.10M	4.96M	6.25M	884.00K	-2.19M	8.46M	10.15M	8.04M	7.06M	9.79M	6.90M	7.09M	1.37M	500.00K	0.00	104.67M	0.00	6.25M	4.60M	3.70M	2.60M	1.30M	600.00K	300.00K	200.00K
Operating Expenses	1.34B	1.20B	1.02B	926.75M	908.73M	900.60M	801.90M	745.01M	625.17M	596.16M	578.37M	585.83M	525.33M	473.40M	412.10M	359.99M	348.40M	294.33M	244.47M	167.09M	131.38M	105.85M	184.06M	61.06M	51.73M	38.50M	29.80M	23.20M	15.20M	10.00M	6.70M	4.10M
Cost & Expenses	3.37B	3.07B	2.58B	2.28B	2.15B	1.97B	1.78B	1.61B	1.40B	1.26B	1.14B	1.16B	1.07B	975.22M	848.98M	726.92M	690.05M	626.17M	474.57M	317.73M	253.98M	206.33M	254.89M	111.44M	82.48M	63.30M	49.20M	40.90M	30.90M	20.70M	12.60M	7.00M
Interest Income	0.00	47.38M	22.31M	362.00K	1.02M	2.30M	16.38M	17.09M	16.86M	26.21M	31.24M	38.87M	33.87M	27.80M	16.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	45.71M	47.38M	22.31M	23.99M	40.38M	36.16M	28.36M	28.24M	11.21M	5.78M	6.13M	6.39M	4.79M	1.76M	10.06M	10.06M	10.06M	1.32M	1.32M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	216.21M	196.52M	193.84M	191.52M	181.37M	150.80M	119.96M	112.16M	86.85M	73.06M	9.73M	10.14M	13.97M	10.15M	8.04M	7.06M	59.49M	48.14M	41.62M	29.13M	17.87M	12.58M	9.97M	8.45M	6.25M	4.60M	3.70M	2.60M	1.30M	600.00K	300.00K	200.00K
EBITDA	1.53B	1.36B	1.18B	1.10B	990.43M	705.80M	680.22M	568.89M	522.72M	482.29M	484.87M	469.79M	422.59M	374.32M	322.15M	190.31M	204.83M	90.16M	174.04M	136.90M	85.36M	79.82M	-40.84M	52.16M	39.39M	29.90M	21.00M	10.90M	4.90M	3.40M	1.60M	900.00K
EBITDA Ratio	32.73%	31.72%	33.37%	34.80%	33.47%	32.36%	29.85%	29.02%	29.40%	29.44%	27.49%	24.10%	22.68%	23.31%	22.73%	22.07%	24.47%	19.12%	28.86%	34.72%	30.28%	28.29%	-21.95%	43.70%	33.87%	35.44%	33.53%	16.46%	5.78%	10.21%	7.91%	3.90%
Operating Income	1.32B	1.13B	1.00B	903.68M	809.66M	579.26M	541.83M	425.80M	428.95M	409.24M	405.09M	354.82M	294.41M	266.92M	240.38M	190.31M	142.97M	90.16M	131.30M	97.35M	85.36M	67.24M	-51.16M	26.04M	33.14M	25.30M	17.30M	8.30M	3.70M	2.80M	1.30M	700.00K
Operating Income Ratio	28.17%	26.80%	27.96%	28.27%	27.38%	22.22%	23.15%	20.60%	23.33%	24.38%	26.05%	23.43%	21.51%	21.47%	22.01%	20.67%	17.11%	12.59%	21.63%	22.88%	25.16%	24.58%	-25.07%	16.78%	28.66%	28.56%	26.02%	16.87%	10.69%	11.91%	9.35%	9.09%
Total Other Income/Expenses	-55.10M	-30.21M	-39.80M	-20.02M	-76.57M	-60.42M	-20.52M	-7.06M	10.61M	26.68M	25.99M	30.30M	37.54M	36.78M	20.21M	11.37M	14.89M	7.81M	2.09M	-727.00K	-693.00K	-113.00K	105.75M	1.27M	1.03M	-700.00K	-1.20M	2.80M	2.90M	900.00K	500.00K	500.00K
Income Before Tax	1.26B	1.10B	960.48M	883.66M	733.09M	518.85M	521.31M	418.74M	439.57M	435.92M	431.08M	385.12M	331.95M	303.71M	260.59M	201.68M	157.86M	97.97M	133.39M	96.63M	84.67M	67.13M	54.59M	27.31M	34.17M	24.60M	16.10M	11.10M	6.60M	3.70M	1.80M	1.20M
Income Before Tax Ratio	27.00%	26.09%	26.84%	27.64%	24.79%	19.91%	22.28%	20.26%	23.91%	25.96%	27.72%	25.43%	24.26%	24.43%	23.86%	21.90%	18.90%	13.68%	21.98%	22.71%	24.95%	24.54%	26.75%	17.60%	29.55%	27.77%	24.21%	22.56%	19.08%	15.74%	12.95%	15.58%
Income Tax Expense	243.85M	204.11M	181.05M	409.16M	111.41M	114.26M	205.72M	76.46M	87.16M	83.03M	85.81M	77.99M	77.10M	76.72M	70.50M	55.24M	47.55M	31.67M	45.18M	31.84M	27.38M	21.40M	17.09M	15.68M	11.94M	8.50M	5.50M	3.60M	2.10M	900.00K	600.00K	400.00K
Net Income	1.02B	897.56M	779.44M	474.51M	621.67M	404.59M	315.59M	342.28M	352.41M	352.89M	345.27M	307.13M	254.85M	226.99M	190.09M	146.45M	110.30M	66.30M	88.21M	64.79M	57.28M	45.73M	37.51M	11.63M	22.23M	16.10M	10.60M	7.50M	4.50M	2.80M	1.20M	800.00K
Net Income Ratio	21.79%	21.25%	21.78%	14.84%	21.02%	15.52%	13.49%	16.56%	19.17%	21.02%	22.20%	20.28%	18.62%	18.26%	17.40%	15.91%	13.20%	9.26%	14.53%	15.23%	16.88%	16.72%	18.38%	7.50%	19.22%	18.17%	15.94%	15.24%	13.01%	11.91%	8.63%	10.39%
EPS	6.94	6.12	5.34	3.27	4.31	2.83	2.21	2.42	2.51	2.51	2.44	2.15	1.75	1.49	1.26	0.97	0.72	0.43	0.61	0.47	0.43	0.35	0.29	0.09	0.19	0.14	0.09	0.06	0.04	0.04	0.02	0.02
EPS Diluted	6.92	6.09	5.30	3.24	4.27	2.80	2.19	2.40	2.49	2.47	2.39	2.10	1.71	1.44	1.23	0.95	0.70	0.43	0.58	0.46	0.41	0.33	0.28	0.09	0.17	0.13	0.09	0.06	0.04	0.04	0.02	0.02
Weighted Avg Shares Out	147.02M	146.77M	146.07M	145.31M	144.34M	143.11M	142.76M	141.36M	140.24M	140.47M	141.47M	142.95M	145.90M	152.47M	150.91M	151.26M	154.76M	153.42M	144.61M	137.29M	134.78M	132.22M	128.70M	124.52M	120.61M	117.66M	116.16M	117.07M	112.50M	70.00M	53.33M	48.00M
Weighted Avg Shares Out (Dil)	147.55M	147.46M	147.04M	146.45M	145.65M	144.48M	143.99M	142.45M	141.67M	142.69M	144.36M	146.41M	149.32M	157.20M	155.10M	154.23M	157.42M	156.51M	154.32M	149.88M	140.50M	137.76M	136.32M	133.94M	129.21M	124.27M	120.28M	117.07M	112.50M	70.00M	53.33M	48.00M

ResMed Inc. (RMD) Q4 2024 Earnings Call Transcript

August 1, 2024seekingalpha.com

ResMed Inc. (NYSE:RMD ) Q4 2024 Earnings Conference Call August 031, 2024, 04:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Michael Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call...

Compared to Estimates, ResMed (RMD) Q4 Earnings: A Look at Key Metrics

August 1, 2024zacks.com

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...

ResMed (RMD) Beats Q4 Earnings and Revenue Estimates

August 1, 2024zacks.com

ResMed (RMD) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.60 per share a year ago.

ResMed meets estimates on steady demand for its sleep apnea devices

August 1, 2024reuters.com

Medical equipment maker ResMed reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices.

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024

August 1, 2024globenewswire.com

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money

August 1, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results...

Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

July 30, 2024zacks.com

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

July 30, 2024zacks.com

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities Laws - RMD

July 30, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results...

Seeking Clues to ResMed (RMD) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

July 29, 2024zacks.com

Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

ResMed Inc. (RMD) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories